Analyst Ryan MacDonald from Needham maintained a Buy rating on Phreesia (PHR – Research Report) and keeping the price target at $29.00. Discover outperforming stocks and invest smarter with Top ...
Hosted on MSN16d
RBC Capital Upgrades Phreesia (PHR)Analyst Price Forecast Suggests 8.40% Upside As of December 24, 2024, the average one-year price target for Phreesia is $30.82/share. The forecasts range from a low of $24.24 to a high of $37.80.
Phreesia, Inc. (NYSE:PHR), a leading healthcare technology company specializing in patient intake management and workflow optimization, has been garnering attention from analysts and investors ...
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. TipRanks is the most comprehensive data set of sell side ...
On Wednesday, RBC Capital Markets upgraded Phreesia Inc . (NYSE:PHR) stock, a leading healthcare software company, from Sector Perform to Outperform, with a new price target set at $32.00, up from the ...
KeyBanc raised the firm’s price target on Phreesia (PHR) to $30 from $28 and keeps an Overweight rating on the shares. The firm notes healthcare technology stocks were under pressure for most of ...
DA Davidson analyst William Jellison keeps a Buy rating and $36 price target on Phreesia (PHR) while naming the company the firm’s 2025 top pick in Vertical Software. The stock remains “poorly ...
NeuroXess, a Chinese startup, has made two major breakthroughs in brain-computer interface (BCI) technology, coming to the aid of a brain-damaged patient. The first was its ability to decode ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback